Angiotensin-converting enzyme 2 attenuates bleomycin-induced lung fibrosis in mice

Cellular Physiology and Biochemistry

Volumn 36, Issue 2, 2015, Pages 697-711

  Wang, Lifang ^a,b,d   Wang, Yuxiang ^a,c   Yang, Tuo ^a,b,e   Guo, Yanfei ^a,b   Sun, Tieying ^a,b  

^a PEKING UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^d CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

ACE2; Alveolitis; Bleomycin; Lung fibrosis; RAS

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSINOGEN; CD45 ANTIGEN; COLLAGEN; CYTOKINE; HYDROXYPROLINE; RAS PROTEIN; SURFACTANT PROTEIN A; TRANSFORMING GROWTH FACTOR BETA1; ANTIINFLAMMATORY AGENT; BLEOMYCIN; DIPEPTIDYL CARBOXYPEPTIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIAPOPTOTIC ACTIVITY; ANTIFIBROTIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BLEOMYCIN-INDUCED PULMONARY FIBROSIS; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG TARGETING; EPITHELIZATION; FIBROGENESIS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LUNG ALVEOLUS EPITHELIUM; LUNG FIBROBLAST; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; TUNEL ASSAY; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; FIBROBLAST; LUNG; METABOLISM; PATHOLOGY; PULMONARY FIBROSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

MUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; BLEOMYCIN; FIBROBLASTS; LUNG; MALE; MICE; MICE, INBRED C57BL; PEPTIDYL-DIPEPTIDASE A; PULMONARY FIBROSIS; RENIN-ANGIOTENSIN SYSTEM;

EID: 84929671589     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000430131     Document Type: Article

References (63)

1. Swigris JJ, Stewart AL, Gould MK, Wilson SR: Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. Health Qual Life OutDOI: 10.1186/1477-7525-3-61.
2. Nho RS: Current concept for the pathogenesis of idiopathic pulmonary fibrosis. Clin Res Pulmono 2013;1:1006-1008.
3. Navaratnam VI, Fleming KM, West J, Smith CJ, Jenkins RG, Fogarty A, Hubbard RB: The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax 2011;66:462-467.
4. Selman M, Pardo A: Role of epithelial cells in idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006;3:364-372.
5. Wallace WA, Howie SE: Immunoreactive interleukin 4 and interferon-gamma expression by type II alveolar epithelial cells in interstitial lung disease. J Pathol 1999;187:475-480.
6. Semenzato G, Adami F, Maschio N, Agostini C: Immune mechanisms in interstitial lung diseases. Allergy 2000;15:1103-1120.
7. Beers MF, Morrisey EE: The three R's of lung health and disease: repair, remodeling, and regeneration. J Clin Invest 2011;121:2065-2073.
8. Li X, Molina MM, Abdul HA, Ramirez J, Serrano MA, Xaubet A, Uhal BD: Extravascular sources of lung angiotensin peptide synthesis in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2006;291:887-895.
9. Uhal BD, Dang MT, Li X, Abdul HA: Angiotensinogen gene transcription in pulmonary fibrosis. Int J Pept DOI:10.1155/2012/875910.
10. Wang R, Alam G, Zagariya A, Gidea C, Pinillos H, Lalude O, Choudhary G, Oezatalay D, Uhal BD: Apoptosis of lung epithelial cells in response to TNF-A requires angiotensin II generation de novo. J Cell Physiol 2000;185:253-259.
11. Guo L, Richardson KS, Tucker LM, Doll MA, Hein DW, Arteel GE: Role of the renin-angiotensin system in hepatic ischemia reperfusion injury in rats. Hepatology 2004;40:583-589.
12. Chipitsyna G, Gong Q, Gray CF, Haroon Y, Kamer E, Arafat HA: Induction of monocyte chemoattractant protein-1 expression by angiotensin II in the pancreatic islets and beta-cells. Endocrinology 2007;148:2198-2208.
13. Benigni A, Cassis P, Remuzzi G: Angiotensin II revisited: new roles in inflammation, immunology and aging. Embo Mol Med 2010;2:247-257.
14. Uhal BD, Kim JK, Li X, Molina MM: Angiotensin-TGF-beta 1 crosstalk in human idiopathic pulmonary fibrosis: antocrine mechanisms in myofibroblasts and macrophages. Curr Pharm Des 2007;13:1247-1256.
15. Ferrario CM: ACE2: more of Ang-(l-7) or less Ang II? Curr Opin Nephrol Hypertens 2011;20:1-6.
16. Simoes e Silva AC, Silveira KD, Ferreira AJ, Teixeira MM: ACE2, angiotensin-(l-7) and Mas receptor axis in inflammation and fibrosis. Brit J Pharmacol 2013;169:477-492.
17. Ocaranza MP, Jalil JE: Protective role of the ACE2/Ang-(l-9) axis in cardiovascular remodeling. Int J Hypert DOI: 10.1155/2012/594361.
18. Li X, Maria MM, Abdul HA, Uhal V, Xaubet A, Uhal BD: Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2008;295:178-185.
19. Szapiel SV, Elson NA, Fulmer JD, Hunninghake GW, Crystal RG: Bleomycin-induced interstitial pulmonary diseases in the nude, athymic mouse. Am Rev Resp Dis 1979;120:893-899.
20. Prasad K, Prabhu GK: Image analysis tools for evaluation of microscopic views of immunohistochemically stained specimen in medical research-A review. J Med Syst 2012;36:2621-2631.
21. Wang CJ, Zhou ZG, Holmqvist A, Zhang H, Li Y, Adell G, Sun XF: Survivin expression quantified by image pro-plus compared with visual assessment. Appl Immunol 2009;17:530-535.
22. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G: Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Cri Care Med 2006;174:810-816.
23. Panos RJ, Mortenson RL, Niccoli SA, King TE Jr: Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 1990; 88:396-404.
24. Wells AU: The revised ATS/ERS/JRS/ALAT diagnostic criteria for idiopathic pulmonary fibrosis (IPF)-practical implications. Respir Res DOI: 10.1186/1465-9921-14-80.
25. Garcia SC, Buendia RI, Fernandez-Plataa MR, Navarroa C, Perez-Padillaa R, Vargasa MH, Loydb JE, Selmana M: Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. Respir Med 2011;105:1902-1907.
26. Harari S, Caminati A: IPF: new insight on pathogenesis and treatment. Allergy 2010;65:537-553.
27. Jin HL, Dong JC: Pathogenesis of idiopathic pulmonary fibrosis: from initial apoptosis of epithelial cells to lung remodeling. Chin Med J 2011;124:4330-4338.
28. Wolters PJ, Collard HR, Jones KD: Pathogenesis of idiopathic pulmonary fibrosis. Ann Rev Pathol DOI: 10.1146/annurev-pathol-012513-104706.
29. Moeller A, Askc K, Warburtond D, Gauldiec J, Kolba M: The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 2008;40:362-382.
30. Scotton CJ, Chambers RC: Bleomycin revisited: towards a more representative model of IPF? Am J Physiol Lung Cell Mol Physiol 2010;299:439-441.
31. Lo CS, Liu F, Shi Y, Maachi H, Chenier I, Godin N, Filep JG, Ingelfinger JR, Zhang SL, Chan JS: Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice. Am J Physiol Renal Physiol 2012;302:840-852.
32. Couluris M, Kinder BW, Xu P, Gross-King M, Krischer J, Panos RJ: Treatment of idiopathic pulmonary fibrosis with losartan: A pilot project. Lung 2012;190:523-527.
33. Nadrous HF, Olson EJ, Douglas WW, Decker PA, Nadrous JH: Idiopathic pulmonary fibrosis: impact of angiotensin converting enzyme inhibitors and HMG-CoA reductase inhibitors on survival. Chest DOI:10.1378/chest.l24.4-MeetingAbstracts.ll6S-a.
34. Hunninghake GM: A new hope for idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2142-2143.
35. Uhal BD, Li X, Piasecki CC, Molina-Molina M: Angiotensin signalling in pulmonary fibrosis. J Biochem Cell Biol 2012;44:465-468.
36. Wang T, Han SX, Zhang SF, Ning YY, Chen L, Chen YJ, He GM, Xu D, An J, Yang T, Zhang XH, Wen FQ: Role of chymase in cigarette smoke-induced pulmonary artery remodeling and pulmonary hypertension in hamsters. Respir Res DOI:10.1186/1465-9921-ll-36.
37. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC: Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet DOI:10.1016/S1470-2045(10)70106-6.
38. Mii A, Shimizu A, Masuda Y, Ishizaki M, Kawachi H, lino Y, Katayama Y, Fukuda Y: Angiotensin II receptor blockade inhibits acute glomerular injuries with the alteration of receptor expression. Lab Invest 2009;89:164-177.
39. Waseda Y, Yasui M, Nishizawa Y, Inuzuka K, Takato H, Ichikawa Y, Tagami A, Fujimura M, Nakao S: Angiotensin II type 2 receptor antagonist reduces bleomycin-induced pulmonary fibrosis in mice. Respir Res2008;9:43.
40. Dong B, Yu QT, Dai HY, Gao YY, Zhou ZL, Zhang L, Jiang H, Gao F, Li SY, Zhang YH, Bian HJ, Liu CX, Wang N, Xu H, Pan CM, Song HD, Zhang C, Zhang Y: Angiotensin-converting enzyme-2 over expression improves left ventricular remodeling and function in a rat model of diabetic cardiomyopathy. J Am Coll Cardiol 2012;59:739-747.
41. Uhal BD, Nguyen H, Dang M, Gopallawa I, Jiang J, Dang V, Ono S, Morimoto K: Abrogation of ER stress-induced apoptosis of alveolar epithelial cells by Angiotensinl-7. Am J Physiol Lung Cell Mol Physiol 2013;305:33-41.
42. King TE Jr, Pardo A, Selman M: Idiopathic pulmonary fibrosis. Lancet 2011;378:1949-1961.
43. Harari S, Caminati A: IPF: new insight on pathogenesis and treatment. Allergy 2010;65:537-553.
44. Kawanami O, Ferrans VJ, Crystal RG: Structure of alveolar epithelial cells in patients with fibrotic lung disorders. Lab Invest 1982;46:39-53.
45. Biswas R, Bunderson-Schelvan M, Holian A: Potential role of the inflammasome-derived inflammatory cytokines in pulmonary fibrosis. Pulm Med DOI: 10.1155/2011/105707.
46. Bonfield TL, Panuska JR, Konstan MW, Hilliard KA, Hilliard JB, Ghnaim H, Berger M: Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995;52:2111-2118.
47. Uhal BD: Apoptosis in lung fibrosis and repair. Chest 2002;122:293-298.
48. Dong Z, Saikumar P, Weinberg JM, Venkatachalam MA: Internucleosomal DNA cleavage triggered by plasma membrane damage during necrotic cell death. Involvement of serine but not cysteine proteases. Am J Pathol 1997;151:1205-1213.
49. Schulze-osthoff K, Bantel H: Necrosis versus apoptosis in acetaminophen-induced hepatotoxicity. Hepatology2011;1053:1070.
50. Thannickal VJ, Horowitz JC: Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006;3:350-356.
51. Phelps DS, Umstead TM, Mejia M, Carrillo G, Pardo A, Selman M: Increased surfactant protein-A levels in patients with newly diagnosed idiopathic pulmonary fibrosis. Chest 2004;2:67-625.
52. Greene KE, King TE Jr, Kuroki Y, Bucher-Bartelson B, Hunninghake GW, Newman LS, Nagae H, Mason RJ: Serum surfactant proteins-A and-D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J 2002;3:439-446.
53. McCormack FX, King TE Jr, Bucher BL, Nielsen L, Mason RJ: Surfactant protein A predicts survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1995;152:751-759.
54. Khalil N, Bereznay O, Sporn M, Greenberg AH: Macrophage production of transforming growth factorpl and collagen synthesis in chronic pulmonary inflammation. J Exp Med 1989;170:723.
55. Kelly Ml, Kolb M, Bonniaud P, Gauldie J: Re-evaluation of fibrogenic cytokines in lung fibrosis. Curr Pharm Des 2003;9:39-49.
56. Meng Y, Yu CH, Li W, Li T, Luo W, Huang S, Wu PS, Cai SX, Li X: Angiotensin-converting enzyme2/ angiotensin-(l-7)/Mas axis protects against lung fibrosis by inhibiting the MAPK/NF-icB pathway. Am J Respir Cell Mol Bio DOI: 10.1165/rcmb.2012-0451OC.
57. Coker RK, Laurent GJ: Pulmonary fibrosis: Cytokines in balance. Eur Respir J 1998;11:1218.
58. Lee TC, Gold LI, Reibman J, Aston C, Begin R, Rom WN, Jagirdar J: Immunohistochemical localization of transforming growth factor-beta and insulin-like growth factor-I in asbestosis in the sheep model. Int Arch Occup Environ Health 1997;69:157-164.
59. Qian YR, Guo Y, Wan HY, Fan L, Feng Y, Ni L, Xiang Y, Li QY: Angiotensin-converting enzyme 2 attenuates the metastasis of non-small cell lung cancer through inhibition of epithelial-mesenchymal transition. Oncol Rep 2013;29:2408-2414.
60. Fernandez IE, Eickelberg O: The impact of TGF-p on lung fibrosis: from targeting to biomarkers. Proc Am Thrac Soc 2012;9:111-116.
61. Shenoy V, Ferreira AJ, Qi Y, Fraga-Silva RA, Diez-Freire C, Dooies A, Jun JY, Sriramula S, Mariappan N, Pourang D, Venugopal CS, Francis J, Reudelhuber T, Santos RA, Patel JM, Raizada MK, Katovich MJ: The angiotensin-converting enzyme 2/angiogenesis-(l-7)/Mas axis confers cardiopulmonary protection againstlung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2010;182:1065-1072.
62. Scotton CJ, Chambers RC: Molecular targets in pulmonary fibrosis: The myofibroblast in focus. Chest 2007;132:1311-1321.
63. Sem HP: The myofibroblast in pulmonary fibrosis. Chest 2002;122:286-289.